The 2-Minute Rule for Milademetan
All enrolled individuals who acquired at the very least a person dose of zosuquidar or placebo through induction were monitored for the event of adverse functions (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions had been relevant to the duration of extended and major myelosuppression as is expected with induction